The King Kong of New Drugs: 3 Companies at the Forefront of the Weight-Loss Revolution



“Sales could hit $200 billion in ten years.”  – CNBC

New Breakthrough Treatment Can

“Switch Off” Hunger
in Minutes

The Wall Street Journal Reports: It could be pharma's biggest blockbuster yet.”
Fortune Reports: “It's expected to be one of the best-selling drugs of all time.”
UBS Bank predicts it will become: “The Biggest Drug Ever.”

Our research proves that anyone who gets in today
could see a 678% return on the drug company that makes it.

Dear Reader,

See this pill…this one right here –

The Wall Street Journal calls this new drug “King Kong”…

Barron’s says it will be a “blockbuster”…

And The New York Post calls it “game-changing”…

That’s because this tiny pill is predicted to help as many as 132 million Americans
live longer, healthier and happier lives.

While saving the lives of as many as 620,192 Americans each and every year. 

And it won’t just save lives. 

According to statistics from the Centers for Disease Control, people who take this pill could save as much as $1,861 a year in medical costs…

…while the U.S. could save as much as $173 billion a year in Medicare and Medicaid costs. 

That’s why drug company insiders, doctors and government agencies believe this could be the biggest selling drug of all time. 

Bloomberg News predicts it will grow into a $150 billion market by 2030. 

Barclays Bank predicts it will grow into a $200 billion market by 2030. 

And Morgan Stanley predicts doctors will write 250 million prescriptions a year by 2030. 

That’s unprecedented growth for a drug when you consider that…

  • It took Lipitor 27 years to reach 114 million prescriptions a year. 
  • It took Metformin 28 years to reach 92 million prescriptions a year. 
  • And it took Zoloft 33 years to reach 38 million prescriptions a year.

Yet by 2023, this remarkable drug will be BIGGER than Lipitor, Metformin and Zoloft… COMBINED.

In fact, if you were to look at sales of these four drugs today, they would look a lot like these marbles.

But demand for this drug is expected to surge 8,595% in the next seven years…blossoming into a $200 billion + industry. 

By 2030, the landscape will look like this – 

That’s why companies are rushing at breakneck speed to get in on the action. 

Pfizer is investing in it….

Johnson & Johnson is investing in it…

Eli Lilly is investing in it…

Glaxo is investing in it…

Novo Nordisk is investing in it…

Reuters calls it a “modern day gold rush for drug makers”…

The Financial Times reported that “The race is on”…

Never before has the drug industry rushed to invest in such a big opportunity.

CNBC reported that this drug could hit sales of “$200 billion within the next decade.” 

Barclays Bank calls it “the story of the decade.”

And it’s not just Big Pharma getting in on the action.

Governments around the world are starting to swing into action….

The World Health Organization estimates this drug could help 1 billion people worldwide, 650 million adults and 340 million adolescents. 

Republican Sen Bill Cassidy (R., LA) introduced legislation to have Medicare pay for the drug.

This drug is not just a game changer.

It is the game changer.

And it could mint more millionaires than any other innovation in history. More than the steam engine, more than automobiles and more than the Internet.

It only generated $2.3 billion in sales last year. 

But experts project it to go exponential… and soar to $200 billion by 2030.

That’s 19,000% growth!

In a moment, I’ll tell you about the one little pill that's at the forefront of this medical revolution, and who makes it.

Most importantly, I’ll give you specifics on how you can personally profit from it. In fact, if my analysis is correct, this could be the biggest biotech winner you’ve ever had. 

You will soon understand how these types of gains are possible once you see how this treatment works – and how it will benefit the companies, countries and governments who use it.

First, it’s important for you to know who I am, and why I’ve never been so certain about anything in my life…

My Name is Dylan Jovine

My name is Dylan Jovine.

I started my career on Wall Street in 1991. 

That’s when I was hired by Peter Jaquith, one of the investment bankers who became famous for saving New York City from bankruptcy in the 1970s’.

That was a big break for a kid who grew up dirt poor on welfare and food stamps in Queens, New York. I wasn’t going to waste it.

I managed accounts. But I fell in love with researching stocks.

Studying a stock was like reading a short history book about the town the company was in, the people that worked there and the products they made. I loved it. I couldn’t believe people got paid to do this. 

Within three years, I earned a reputation for picking stocks right before they were taken over.

Stocks like Paramount which was bought out by Viacom three months after I recommended it for a fast 100% gain. 

Or the easy 70% gains we made when US Reinsurance was acquired six months after I recommended it.

Or the fast 78% gains we booked when Chase Manhattan Bank was acquired by Chemical Bank.

Or the extra 83.3% profit we made when Michigan national Bank was acquired for $110.

Remember, this is the early 1990’s –  before the internet bull market of the 1990’s. 

And here I am this 23-year old kid picking takeover after takeover. 

By 1996, my clients bankrolled me to start my own brokerage firm. 

And that’s how, at just 24 years old, I became one of the youngest people in American history to launch a registered broker-dealer and market-maker. 

Our office were at 100 Wall Street, below…

Offices at 100 Wall Street

Since Predicting the 2009 Market Crash I Was Invited onto Fox Business & CNBC

Because of what I accomplished at such a young age Wall Street took notice. 

But it wasn’t until I predicted the 2008-09 financial crisis and crash a year before it happened that the general public took notice. 

That’s when I was invited onto places like Fox Business News and CNBC to share my opinion.   

My message was simple: 

The stock market at 6,500 is like walking into your dealership when everything is on sale marked 90% off! 

Like the easy 624% returns we booked after buying American Express at $14.24 a share. 

Or the fast 700% profits with Starbucks which I bought at $8 which then soared to a high of $56.

Or the hidden 459% profits we found buying shares of AutoNation between $10 – $11 a share.

Or the speedy 235% gains that came from those who bought FactSet Research with us at $63.23.

Or John Harland which was acquired six months after I recommended it, giving investors a fast 35% gain.

Or shares of K-Swiss, which gave my clients an easy 65% gain.

And remember Radio Shack? I brought investors fast 80% profits after the stock soared from $16 to $29.

Or the stellar 40% gains we earned when Hilton Hotels was taken private.

Now I don’t say all this up to brag. 

I say it to show you that I’ve been making money for myself and my clients for close to thirty years. I know what I’m doing.

My Love of Biotech is Personal

But as great as these gains are, I fully believe the opportunity that this little pill presents could make even bigger gains … 

You have the chance to be at the beginning of a massive opportunity – and earn life-changing profits.

Of course, there are no guarantees in the financial markets. But the potential behind this medical revolution is undeniable as it grows 5,700% into a $200 billion drug. If it does only half of what I'm expecting, it could make you incredibly wealthy.

Imagine what you could do with those types of profits. Perhaps you would use that newfound money to retire earlier than you ever thought possible and buy that dream house you’ve always wanted.

That’s what I did. But not in triumph.  

In 2013, I became sick. I won’t mention the details in public, but let’s just say the sickness almost destroyed my life.

My work began to suffer.

I just couldn’t think straight. I couldn’t put my thoughts together. Partners and employees started to work around me.

It didn’t matter that I was the Founder & CEO of the company. I was a sick man and was treated as such.

I could barely focus, let alone run a company. All I wanted to do is sleep all day. So that’s what I did.

It wasn’t long before I had to resign from the company I founded. Thankfully, I had enough money in the bank to retire. 

Two years and many doctors later, I found one who helped. He asked if I’d be interested in enrolling in an experimental gene-therapy program that custom-tailors treatments based on my genetic profile.

Instead of chemical medicines, he would recommend customized treatments based on my personal test results. I was so desperate I agreed.

We’ve made a dozen or so adjustments like that based on my genetic profile and I slowly started to get well. A year or so later I started to feel like my old self again.

And then the investor in me took over. I started asking questions.

What company was behind these genetic tests? Is the company publicly traded?  What other companies do this? What else do they treat? Are they publicly traded?

And who else knows about this?

Nobody did.

It was like a secret bull market happening in our bathrooms.

It was staring me in the face when I brushed my teeth in the morning. But it seemed nobody was talking about it, outside of a small group of scientists and investors. Nobody.

That was in 2016.

My Long Road Back
After Illness

In March of 2018, I decided to do something revolutionary: I came out of retirement to let people know about the biotech stocks I liked, so they know exactly which ones to to buy, when to buy and when to sell.

But I have to admit – I was a bit nervous. It had been years since I recommended stocks to paying customers. That adds a lot of pressure you don’t have when investing with your own money. 

I knew I’d be rusty. But I wasn’t sure how rusty. 

My first recommendation was CASI Pharma. I recommended it at $3.48 in March of 2018. I recommended selling the stock at $7.97, for a 129% gain.

My second pick was Mirati Therapeutics.  In April of 2018, I recommended shares at $26.25. When the stock hit $52.40, I recommended selling for a 99% gain. 

I hit a speed bump on my third pick, Immunogen, which dropped 66% from our recommended price. I guess I was still a bit rusty. 

But I more than made up for it on my next two picks. 

My fourth pick was Loxo Oncology, which I recommended at $131 a share. Folks who followed my advice made 78% gains when they sold it.

And my fifth recommendation was Tesaro, which I recommended at $38.41 a share. Folks who followed my advice made 93% gains when they sold it.

The results were in: I may not have been tip-top shape yet, but it was clear I still had my fastball.

The World Moves Much Faster
Today than it Did 30 Years Ago

But it won’t take 30 years for this to happen. The world moves much faster today than it did in the 1980’s (for better and worse). 

And here the gains will be even bigger. It could impact more lives. 

I know that’s a huge claim.

But there’s a reason the world’s greatest investors, governments, and Wall Street investments banks are so bullish on this new drug. They see an opportunity to ride a drug class that’s expected to grow 19,000% in the next decade. 

And you have the rare opportunity to get on board with them today.

On the cutting-edge of this breakthrough drug from a well-positioned company that’s ready to begin massive production of this little drug….

Before I tell you more about this company, and how to position yourself before the mainstream catches wind, I need to let you in on a secret.

It’s the secret that helped me picked all those biotech winners I showed you earlier. 

You see, the biggest mistake investors make when picking biotech stocks is not picking them at the right time in their clinical trial cycle.

Take a look for yourself.

The 3 Stages of FDA Approval

A typical FDA clinical trial has 3 Phases. 

Phase 1 is a test for safety and dosing.

In this phase, scientists aren’t really testing to see if the drug works. They’re testing to see if there are any adverse side effects. 

They do this by using a small group of between 20 and 80 people. 

The good news is that roughly 63.2% of all drugs make it out of Phase 1. 

The bad news is that I call this the “stock promoter phase”… 

That’s because the small biotech’s that tend to run up in Phase 1 often do so because of good public relations as much as anything. 

Phase 2 expands the test.  

Phase 2 tests can include hundreds of people. 

While safety and dosing are being evaluated, it’s really the first time that scientists are looking to see if the drug actually works. 

And that’s what makes Phase 2 very risky: only 30% of drugs make it out of Phase 2 and onto Phase 3.

The final phase Phase 3.

Phase 3 tests can include thousands of people. 

In addition to side effects, the big focus of Phase 3 is to see how well the drug works at different dosing regiments. 

Find a company with a safe drug that can impact a massive market that’s in Phase 3 trials – and generational wealth can be made. 

That’s where we’ve had most of our success. 

Just like the “King Kong” drug that I’ve been talking about. 

That’s why I’ve spent four weeks in front of my computer rushing to get this out to you. This innovative company looks ready to take off, and I want you to have the opportunity to make life-changing gains.

Understanding this very simple diagram is what has allowed me to spot ChemoCentryx as it was moving from Phase 2 to Phase 3…delivering gains of 435%

The same thing happened with Krystal Biotech. A lot of folks got in too early and rode the ups and downs for years. But we recommended it when it crossed from Phase 2 to Phase 3, delivering gains of 275%.

Same for Kura Oncology. When that stock entered Phase 3 trials, I recommended shares which delivered gains of 124%.

And it happened recently with Immunogen. We recommended shares at $5.30 and when the company won FDA approval for their new drug that treats cervical cancer, shares soared 134% in one day.

Of course, the key is to know when a drug is going from Phase 2 to Phase 3 – or when it seems likely to move from Phase 3 to FDA approval. That’s why I wake up at 4am most mornings to do my research and read more by noon than most people do all week.

Again, Lipitor, Zoloft and Metformin have been on the market for 30 years and sell 244 million prescriptions per year – COMBINED. 

But Morgan Stanley predicts doctors will write 250 million prescriptions a year of this drug by 2030.

There’s no question in my mind that those who move fast will create massive wealth. 

I’ve never been more certain of anything in my 30+ year career.

So what is this new drug The Wall Street Journal calls the “King Kong” of new drugs?

Why does Morgan Stanley think it could cut heart attacks and strokes by 27%?

In short, it’s a drug that will help the country lose weight. In fact, you’ve probably already heard of it. 

Let me explain…

In 2005, scientists at Novo Nordisk of Denmark began testing a new diabetes treatment.

The goal was to create a once-weekly drug to help people control their blood sugar. This would rival popular drugs on the market like Metformin. 

The drug worked, and in December of 2017 was approved for sale in the United States under the name Ozempic. 

But the scientists found a “side effect” they had not originally planned for: patients who take the drug lost between 15 – 20% of their body weight. 

That has driven Big Pharma giants to rush to get out competing weight-loss drugs to market as quickly as possible. 

These new weight-loss drugs belong to a class of medicines called “Glucagon-like peptide-1 agonists,” or GLP-1 for short. 

Here’s how they work.

Case Study:
The New Weight-Loss Drugs

GLP-1 stimulates the production of incretin, a naturally occurring hormone that makes us feel full.

Incretin is special because it tricks both the stomach and the brain. 

It tricks the stomach by slowing the rate the stomach empties itself. This has the effect of making you feel full longer than you would normally.  

I call it the “Thanksgiving Dinner Effect” because a friend of mine who takes it says he feels as full as if he just ate a large meal.

The second trick incretin does is on the brain. 

It does this by sending signals to the hypothalamus, the part of the brain that controls hunger signals. This reduces our hunger signals and cravings.

The result has been miraculous: a recent FDA Phase 3 study shows that a new GLP-1 drug reduced body weight by as astonishing 22%.

Consider this: according to the CDC, an American adult of average height is considered obese when he or she weighs 203 pounds. 

By reducing that weight by 22%, that person would lose 44 pounds!

But taking weight off and keeping it off are two different things.

That’s what’s so astonishing about this drug: the weight stays off as long as you keep taking it (a boom for the drug makers). 

As The New England Journal of Medicine reported these drugs show “substantial and sustained reductions in body weight.”

That’s why –

  • The Atlantic writes that “obesity is about to be old news.”
  • The Wall Street Journal reports, “No anti-obesity drug has ever safely made such a difference.”
  • The New York Post calls them “game-changing.”
  • And NPR calls these new drugs: “revolutionary.”

That’s great for people who struggle with obesity. They get to live longer, healthier lives. 

But it’s the huge size of the market that has drug makers rushing to get out these drugs. 

And that’s what gives investors incredible upside too. 

Let me explain –

A MASSIVE American Market

41.9% of Americans are considered obese, according to the U.S. National Center for Health Statistics.  

That’s 139 million people in the United States that have a Body Mass Index (BMI) of 30 or more. 

But contrary to popular belief, it’s not just the United States that’s obese. Obesity has become a truly global problem. 

Take a look…

The World is Obese Too

Contrary to popular opinion, the United States isn’t even in the top 10 of obese countries. It’s the 11th most obese country on earth.

(Nauru, the tiny island nation of Micronesia, holds the distinction of being the most obese country on earth: 61% of its citizens are obese). 

All told, there are 105 countries with an obesity rate above 20%. Here’s a sample of some of the richest countries on the list – 

  • Kuwait – 37.9% 
  • Saudi Arabia – 35.4% 
  • Turkey – 32% 
  • New Zealand – 30.8% 
  • Canada – 29.4% 
  • Australia – 29% 
  • United Kingdom – 27.8% 
  • Israel – 26.1% 
  • Ireland – 25.3% 
  • Spain – 23.8% 
  • Germany – 22.3%
  • France – 21.6%

The rich countries on this list that also have nationalized healthcare have a strong incentive to pay for this new obesity medicine. 

Morgan Stanley predicts these new drugs “will deliver a 27% reduction in the risk of heart attacks, stroke and cardiovascular deaths.”

That means the countries on this list could save tens of billions of dollars each year if its population was thinner. 

Consider the plight of the United States.  

Obesity Cost the
U.S. $173 Billion in 2019

According to the CDC, the estimated annual medical cost of obesity in the United States was nearly $173 billion in 2019. 

That’s because people are more likely to get obesity-related conditions such as heart disease, stroke, type 2 diabetes and certain types of cancer. 

These are among the leading causes of preventable, premature death. 

That makes this an expensive condition to live with.  

Medical costs for adults who had obesity are $1,861 higher than medical costs for people with healthy weight.

That means society pays an extra $155.08 a month for the 139 million obese people in the United States. 

If Morgan Stanley is right, and these new drugs reduce the risk of heart attacks and strokes by 27%, it could save lives of as many as 620,192 Americans each year alone.  

Benefits this clear are obvious to patients and governments. And they’re finally becoming obvious to investors. 

With a market this big, it’s easy to see why these new weight-loss drugs are expected to be so huge.

That’s why drug company insiders, doctors and government agencies believe this could be the biggest selling drug of all time. 

Barron’s predicts these “Weight-Loss Drugs Will Be Blockbusters.”

Bloomberg News predicts it will grow into a $150 billion market by 2030. 

Barclays Bank predicts it will grow into a $200 billion market by 2030. 

And remember, Morgan Stanley predicts doctors will write 250 million prescriptions a year by 2030. 

That’s unprecedented growth for a drug when you consider that…

  • It took Lipitor 27 years to reach 114 million prescriptions a year. 
  • It took Metformin 28 years to reach 92 million prescriptions a year. 
  • And it took Zoloft 33 years to reach 38 million prescriptions a year.

The best part is we’re just at the beginning of what promises to be a very profitable ride for investors. 

Again, weight loss drugs are just at their infancy. Only one of them has even been approved so far. 

But the big ones are right in our sweet spot in FDA trials – at Phase 3 ready to get FDA approval.

So we’re just at the start….of what promises to be a very fast ride for early investors.

The market for these drugs will grow at an exponential rate – unlike anything the world has ever seen before.

From $2.3 billion today to a staggering $200 billion in the next decade.

That’s an 8,000% growth rate!

Now when most folks think of the great fortunes made in modern times, they think of the tech sector. 

But the drug sector has made some of the greatest fortunes the world has ever seen. The only difference is you that these people don’t publicize their wealth –  

  • Andre Hoffman, of Roche, is worth $35 billion.
  • Dr. Patrick Soon-Shiong, cofounder of APP Pharmaceuticals, is worth $8 billion.
  • Stephane Bancel, co-founder of Moderna, is worth $4 billion. 
  • Dr. Phillip Frost, founder of Ivax, is worth $2.6 billion.
  • Randal “RJ” Kirk, founder of Clinical Data, is worth $2.4 billion.

The drug sector is so lucrative, it turned a $1,000 investment into Amgen into $425,454.

But insiders and experts think these weight-loss drugs are predicted to DWARF any drug every created before it.

And it’s just begun…with the biggest investors in the world pouring billions into the firms making these new drugs.

  • Ray Dalio
  • Paul Tudor Jones
  • Jim Simons
  • Steve Cohen
  • BlackRock Inc.
  • Morgan Stanley
  • Goldman Sachs

The list goes on and on. 

It comes down to this. 

The biggest, smartest, most informed money on Wall Street are loading up…and I urge you to do the same, immediately.

It’s just a matter of time before this secret moves from Wall Street to Main Street. 

And that will happen. It always does. 

By the time your neighbor is telling you about these drug companies, it will be too late.  

And at the center of all of this is one small company that owns the patent on this technology – and whose stock could hand investors 5, 10, 20, even 50 times their money.

A History of Successful
Biotech Investing

Since coming out of retirement in 2018, I’ve helped folks make money buying into unknown biotech stocks before the rest of the world knew about them.

A few winners include:

  • ChemoCentrix which soared 435%
  • Krystal Biotech which jumped 275%
  • Array Biopharma which moved 144%
  • Kura Oncology which jumped 124%
  • Tesaro which jumped 93%
  • Loxo Oncology which soared 78%
  • Casi Pharmaceuticals which jumped 129%
  • Mirati Therapeutics which moved 99%

But here’s the thing…

As remarkable as these gains are…

They don’t compare to what’s in front of us right now.

And while there will be a number of ways to profit in the coming years, there will not be an opportunity like the one before you today.

You see, the dawn of a new medical age is upon us.

This is the very beginning.

The Small Biotech
with the Biggest Upside

And a remarkable – yet overlooked – company offers investors the biggest opportunity of this revolution.

Right now, only a handful of the savviest scientists and investors know about. But that’s starting to change.

If you were to make only one investment in the next decade, this is it. It doesn’t get clearer than this.

Of that I have no doubt.

Here are the details…

As I mentioned, this biotech has the opportunity to radically change how we treat brain diseases.

And the best way to capitalize on this once-in-a-lifetime opportunity is to invest in the small company that made this treatment possible.

Let’s take another look at Biogen.

What started Biogen on such a huge run was its treatment for multiple sclerosis.  And this was back in the dark ages before we had mapped the human genome. They also happened to stay independent, whereas most of their competitors were bought out.

And as I mentioned a few minutes ago, early investors saw massive 42,445% gains.

I am confident investors with the foresight to invest in the right companies during the revolution in weight-loss drugs – before the general public realizes how big this opportunity is – will be rewarded with returns similar to these.

Could Be Taken Over Any Day

But it won’t take 30 years. The world moves a lot faster today than it did three decades ago. It will be done in just four. The company either taken over or takes over the world.

It’s the biggest untold story in medicine – truly the very definition of a revolution – and I haven’t seen one credible source telling investors how to profit from this. It’s mind-boggling.

That’s why I had to tell this story. In my almost 30 years in the markets, I’ve never such a big opportunity. And nobody is talking about it!

But what truly makes this opportunity so special is the urgency behind it.

They just announced results that showed patients lost as much as 6% of their body weight in just 28 days. 

That makes this small biotech a prime takeover candidate.

As medical journal Stat News reported, “It could also make them an appealing takeout candidate to a company that is missing out on the GLP-1 gold rush or that is unsatisfied with its own R&D efforts.”

It doesn’t take a brain surgeon to see what would happen if this company kept having success during their FDA trials. 

Small biotech’s become very attractive takeover targets when their drug could save the federal government billions in Medicaid and Medicare spending.

Below are three biotech takeovers I picked since coming out of retirement –

Array Biopharma jumped 148% in one day when Pfizer bought them because of their new cancer drugs…

When it looked like Tesaro’s new drugs were going to be covered by Medicare, Glaxo bought the company, handing investors 91% profits in one morning.

And Loxo Oncology jumped 71% in one morning after Eli Lilly bought the company.

And here’s the thing…

For the folks who follow my research, I prefer recommending biotech’s on the very forefront of this massive change. The biotech’s that the large companies are partnering with.

That’s where all the innovation is. And that comes in the form of smaller companies with the world’s leading scientists.

My research has led me to a small company has the one thing that matters the most: a patent on a drug that could be the biggest drug in the world.

And they have the two other key ingredients: a strategic partner and a massive market.

And even if a small part of the trillions in potential savings flows toward this small firm, the growth will be through the roof.

Amgen gained 42,000% and they weren’t on the cusp of a wave this big. 

As far as opportunities go, we’re comparing apples to oranges here.

To give you an edge, I’ve put all the details in a special report called “The King Kong of New Drugs: 3 Companies at the Forefront of the Weight-Loss Revolution.”

This groundbreaking new report tells you everything you need to know about the biotech I think gives investors the biggest upside to this weight-loss revolution…so you have a chance to ride this massive trend for 42,000% returns. 

You’ll get the name of the company, the stock symbol, our buy price and what our target sell price is. 

But that’s just the start. 

We’ve added two additional weight-loss drug makers to this blockbuster 100 page report. 

Here are all three companies we cover in this report –

Weight-Loss Stock Pick #1:

“MASSIVE UPSIDE: The Small Biotech

that Could Soar 42,000% if it isn’t

Taken Over First.”

Weight-loss drugs are all about safety and effectiveness.

And this small biotech has had smashing results on both front….

Results for its weight-loss drug were so promising, the company immediately became a top takeover target for a Big Pharma company looking to get into this goldmine.

Weight-Loss Stock Pick #2:

“$20 BILLION BABY: Morgan Stanley’s
#1 Weight-Loss Drug Stock”

Our second weight-loss drug company is on the verge of releasing a drug expected to be a blockbuster. 

Morgan Stanley predicts this drug will do at least $21 billion in sales, making it even bigger than Keytruda, the biggest selling drug in history.

The Wall Street Journal thinks their weight-loss drug could hit $25 billion a year in sales.

Regardless of who’s right, investors will be big winners with this pick.

Weight-Loss Stock Pick #3:

“CELEBRITY: The Weight-Loss Drug
Taking Hollywood by Storm”

The third stock in our special report has already established itself with one of the richest groups around: Hollywood.

That’s given this company a head-start: allowing it to rack up an estimated $2.3 billion in sales last year alone. 


The Micro-Cap that Goldman Sachs thinks Could Double Because of the New Weight-Loss Drug?”

We’ve also added a surprise bonus pick on a micro-cap stock that Goldman Sachs thinks can double because of the new weight-loss mega-trend.

And the party is just getting started for all these stocks.

I detail each of these stocks in our brand-new report, “The King Kong of New Drugs: 3 Companies at the Forefront of the Weight-Loss Revolution.”

And the report is yours – absolutely free.

Profit From Your 21st Century Medicine Cabinet

I want you to have this report for free because there doesn’t seem to be anyone else covering this. 

You see, we’re on the cusp of a revolution in medicine so powerful, it promises to change how we treat disease.

And yet nobody else seems to be talking about this. 

It’s almost surreal. I feel the same way I did before the housing market crashed.

I began warning folks on May 12, 2006, almost two years before the market crashed.

My first target was Wachovia Bank. The stock was selling at $55.82.

Within two years the stock collapsed to $5.54 a share, a loss of over 90%.

And that was just the tip of the iceberg. 

On June 9, 2006, I warned customers that the entire stock market was going to drop. 

At the time I wrote – 

A year later, the Dow Jones Industrial Average began to drop 45%.

The S & P 500 dropped 47%…

And the Nasdaq Composite dropped 54%…

My point is, I have a proven history of being ahead of the crowd. 

That’s why I had to tell this story. There’s a bull market happening in your bathroom – and it’s staring at you in the face every time you brush your teeth!

That’s exactly why I rushed to get you this urgent report, “The King Kong of New Drugs: 3 Companies at the Forefront of the Weight-Loss Revolution.”

There’s one place on earth you can get this new report…

It’s called Behind the Markets.

I’ve put this new report together for members of my exclusive VIP service, Behind the Markets. 

We hunt for stocks with life-changing potential at Behind the Markets. 

The focus of this unique service is simple: we hunt for small, little-known stocks at the forefront of massive changes. 

Stocks that are so far ahead of their competitors, they can change a market….

Stocks with lower share prices…small market capitalizations…and rapidly growing revenue…

Stocks that can put 1,000% gains in your pocket in just months…and change your life.

As soon as you become a member of Behind the Markets, you become part of my “inner circle” – just like my mother – and you’ll get access to every single investment opportunity I discover each month.

As a member of Behind the Markets, you’ll receive:

  • Our Brand-new Report “The King Kong of New Drugs: 3 Companies at the Forefront of the Weight-Loss Revolution.”

This blockbuster 100- page report will outline the three stocks that are changing the very way we’ll treat weight loss in the 21st century. . 

  • You can expect 1-2 new recommendations from me each month.

Each recommendation will include a 30-page report on the company as well as easy-to-follow instructions for you to execute the trade. 

And since we mostly recommend common stocks, these trades will be easy enough for any beginner to do. 

  • You will get Sell Alerts for the opportunity to bank maximum profits.

All you need to do is to wait to hear from me, so you’ll know EXACTLY when it’s time to sell and take profits. This way we can avoid riding a stock up only to ride it all the way back down with no gains to show for it. 

That’s why I won’t recommend selling a position until the trend is officially over. 

  • You will have unlimited access to the Behind the Markets members website.

That’s because all Behind the Markets members will access an exclusive website that you can log on to at your convenience. 

There, you can access all past and present alerts, updates and a few other goodies I will discuss below.

This way, you’ll have a 360-degree view of every open position as well as a record of all the trades we’ve already closed.

You’ll know to the minute how much money Behind the Markets is making for you.

  • You will have VIP concierge service ready to help you Mon-Fri 9am to 5pm 

We have a fully staffed team of professionals who are here solely to help you get the most of out of this opportunity. 

They’re located right here in South Carolina, so you’ll be able to call or email them any day of the week with any questions you may have about your membership.

But most importantly, once you join Behind the Markets, you get access to yours truly – me. 

Like my own family and friends, from now on you’ll know about the big warnings like this first, before the rest of the world knows about them. By the time the general public finds out about this, it will be too late.

You’ll also know EXACTLY what to buy and what to sell, just like my readers did after the market crashed in 2009.

Introductory Offer

I want to position you for the dangerous world that we now find ourselves in.  

Helping you protect your financial security and achieve immense wealth is my mission. 

In short, you get to access a brain that has made millions for myself and for other people during the past three decades. 

This is why I’ve kept the cost of Behind the Markets at the lowest possible level. 

Just $39.

And frankly, I believe it’s a steal at that price.

“The King Kong of New Drugs: 3 Companies at the Forefront of the Weight-Loss Revolution” is worth that alone.

I’ve studied this issue for years and I’ve had my research and writing staff putting together this report for weeks just to get it to you. 

This report hand-delivers three stocks best positioned to profit from the massive changes happening in the way we treat weight loss. 

I don’t know about you, but I’ve been around long enough to know how rare that is. 

But look – as I mentioned earlier, this is about feeding more than my wallet. It’s about feeding my soul. And the best way for me to do that is to help as many people as I can.

And I grew up on welfare and food stamps. So I will never forget the value of a dollar.

And finally, just to prove how confident I am, let me remove any last shred of doubt about this investment.

Try Behind the Markets risk-free for 30 days.  Take the month to review the service. Profit from as many of the open positions as you can. 

If I do not meet or exceed your expectations, just call customer service and you’ll get a 100% full refund. No questions asked. 

PLUS, you can keep the free report you get today.  

Ride this massive defense spending wave with me. 

Sign up for Behind the Markets and let me share with you what I do best each month, just like I do with my friends and family.

Thank you so much for reading this important presentation.

I sincerely hope you’ll take me up on this offer.

I’m confident you’ll look back one day and think that joining Behind the Markets was one of the best financial moves you ever made.

So let me quickly recap what you can expect from Behind the Markets –

  • FREE REPORT: “Our Brand-new Report “The King Kong of New Drugs: 3 Companies at the Forefront of the Weight-Loss Revolution.” You’ll get this invaluable free bonus report right away, as soon as you join. Even if you cancel, it’s yours to keep! Value: $997
  • Life-changing stocks every month: You’ll get the benefit of the best investment experience money can buy in 12 monthly issues of Behind the Markets – e-mailed directly to your inbox. Once you get the email, simply call your broker or place your trade online. Value: $199
  • 30-DAY 100% Money-Back Guarantee: Because I want you to profit from my advice without fear and without hesitation, I’m backing up my claims with an unconditional guarantee: Try Behind the Markets risk free. If you don’t like the service in the first 30 days for any reason whatsoever, every dime you paid toward your membership will be returned to you. The report is yours to keep.

Total Value: $1,196!

All available for the low price today of just $39.

Act Now Before It’s Too Late

The 21st Century revolution in weight loss is one of the biggest opportunities on earth.

While everyone else is focused on old tech stories like EV’s and crypto, this mega-trend is poised to create as many new millionaires as the Internet did for the tech industry. 

But I’m telling you about this early. Nobody else is talking about it. 

It’s because I want my readers to be among the few who have the opportunity to make the kind of money that can change their lives. 

And it starts with the one small company at the center of it all.

But you need to act fast. This tiny biotech could get taken over any day now. 

So just click on the button below to get started.

This one-in-a-lifetime opportunity is yours for the taking.

I urge you to take advantage of it today.

I look forward to having you on board.

“The Buck Stops Here,”

You Might Also Like...

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.